Therapeutic antibodies, including immune checkpoint inhibitors, have shown great success in cancer treatment. In addition to naked monoclonal antibodies (mAbs), antibody-based cancer drug modalities also include bispecific antibodies (BsAbs), antibodies conjugated with drugs (ADCs), oligonucleotides (AOCs), peptides (APECs), or radionuclides (RACs), and scFv antibody fragments used in chimeric antigen receptor (CAR)-T cell therapies. Our antibody core provides state-of-the-art and comprehensive platform technologies and infrastructure for discovering and engineering these antibody-based cancer drug modalities. The core has a diverse human scFv phage-displayed antibody library and successfull...
Read More
Therapeutic antibodies, including immune checkpoint inhibitors, have shown great success in cancer treatment. In addition to naked monoclonal antibodies (mAbs), antibody-based cancer drug modalities also include bispecific antibodies (BsAbs), antibodies conjugated with drugs (ADCs), oligonucleotides (AOCs), peptides (APECs), or radionuclides (RACs), and scFv antibody fragments used in chimeric antigen receptor (CAR)-T cell therapies. Our antibody core provides state-of-the-art and comprehensive platform technologies and infrastructure for discovering and engineering these antibody-based cancer drug modalities. The core has a diverse human scFv phage-displayed antibody library and successfully screened antibodies for novel cancer therapeutics. Our core has established an industry-leading platform for engineering innovative ADCs/AOCs/APECs/RACs. The core has validated a transferrin-receptor (TfR)-mediated brain delivery system for antibody-based therapies to cross the blood-brain barrier (BBB), which affords the design and engineering for antibody therapies for brain tumors such as GBM that currently has limited access to antibody-based therapies. Our core has built a toolbox of antibodies targeting oncogenes and immune checkpoints for engineering bi- and multi-specific antibodies by incorporating specificities and properties of monoclonal antibodies (mAbs) with rational design. The antigen-specific antibody fragment (scFv) is a key component of CAR-T cell therapies. The scFv antibody fragments in our high diversity phage-displayed human antibody library can be used directly for CAR-T constructs. The core is equipped with cutting-edge specialized instruments for discovering and advancing therapeutic antibody leads for preclinical and clinical development. Overall, this unique CPRIT core enables cancer researchers throughout Texas to translate their fundamental discoveries into life-saving antibody-based therapies for cancer patients.
Read Less
|
